Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial

Authors: Bastick, Patricia, Sewak, Sanjeev, Tran, Ben, Pichler, Martin, Shariat, Shahrokh, Rottey, Sylvie, Schatteman, Peter, Schrijvers, Dirk, Verschaeve, Vincent, Vulsteke, Christof, Barros Leite Ferreira, Luiza Aleixo, de Santana Gomes Andrea Juliana, Pereira, Junior, Joao Antonio, Azevedo, Sergio, Bastos, Diogo, Borges, Giuliano, Dettino, Aldo, Antonio, Pires Luis, Luz, Murilo, Martins, Suelen, Mota, Jose Mauricio, Toledo, Joseane, Eigl, Bernhard, Finch, Daygen, Gingerich, Joel, Dong, Haiying, Huang, Jian, Jin, Jie, Pan, Hongming, Sun, Zhongquan, Tian, Ye, Wan, Ben, Wu, Bin, Xu, Ting, Xue, Wei, Zhou, Fangjian, Barthelemy, Philippe, Borchiellini, Delphine, Calcagno, Fabien, Carnot, Aurelien, Cornillon, Pierre, Delva, Remy, Emambux, Sheik, Houede, Nadine, Laguerre, Brigitte, Lauridant, Géraldine, Loriot, Yohann, Mahammedi, Hakim, Maillet, Denis, Pouessel, Damien, Roubaud, Guilhem, Schlurmann-Constans, Friederike, Tosi, Diego, Zanetta, Sylvie, Banek, Severine, Feyerabend, Susan, Kramer, Mario, Niegisch, Guenther, Nuhn, Philipp, Schnabel, Marco, Wuelfing, Christian, Baka, Sofia, Bamias, Aristotelis, Fountzilas, George, Kalofonos, Harabolos, Karalis, Konstantinos, Kotsakis, Athanasios, Timotheadou, Eleni, Landherr, Laszlo, Mangel, Laszlo, Pe’er, Avivit, Levratovsky, Meital, Basso, Umberto, Battelli, Nicola, Cavo, Alessia, De Giorgi, Ugo, Doni, Laura, Galli, Luca, Gigante, Maria Olga, Guadalupi, Valentina, Maio, Michele, Milesi, Laura, Nolè, Franco, Scagliotti, Giorgio, Tortora, Giampaolo, Fukasawa, Satoshi, Harabayashi, Toru, Kamiya, Naoto, Kawahara, Takashi, Kawakita, Mutsushi, Matsubara, Nobunaki, Matsumoto, Kazumasa, Nishimura, Kazuo, Rikiya, Taoka, Shimizu, Nobuaki, Tagaki, Toshio, Kang, Taek Won, Kim, Jwa Hoon, Kim, SeHyun, Lee, Hyo Jin, Lee, Yun-Gyoo, Rha, Sun Young, Seo, Ho Kyung, Los, Maartje, Zurawski, Bogdan, Cortes, Paulo, Faustino, Catia, Vau, Nuno Sineiro, da Luz, Ricardo, Atduev, Vagif, Kirtbaya, Dmitry, Kopyltsov, Evgeny, Lykov, Aleksandr, Marat, Urmantsev, Orlov, Sergey, Penkov, Konstantin, Pirmagomedov, Albert, Semenov, Andrey, Varlamov, Sergey, Anguera, Georgia, Domenech, Montserrat, Girones, Regina, Gonzalez del Alba, Aranzazu, Milagro, Nuria Lainez, Luque, Raquel, Ortega, Esther Martínez, Mellado, Begoña, Méndez Vidal, María Jose, Fernandez, Esteban Nogales, Valderrama, Begoña Perez, Marín, Alvaro Pinto, Santander, Carmen, Huang, Yi-Hsiu, Su, Wen-Pin, Wu, Hung-Chan, Wu, WenJeng, Yu, Kai-Jie, Bilici, Ahmet, Goker, Erdem, Gumus, Mahmut, Karaoglu, Aziz, Kefeli, Umut, Köse, Fatih, Ozguroglu, Mustafa, Tural, Deniz, Turk, Haci, Yalcin, Suayib, Bondarenko, Igor, Khareba, Gennadii, Kidik, Yana, Lychkovskyy, Oleksandr, Sakalo, Valerii, Shevnia, Serghii, Stakhovskyy, Eduard, Bahl, Amit, Crabb, Simon, Powles, Thomas, Sankey, Peter, Sarwar, Mohammad, Benedetto, Pasquale, Burgess, Earle, Dawson, Nancy, Doshi, Gurjyot, Fleming, Mark, Maly, Joseph, Parikh, Mamta, Waterhouse, David, Siefker-Radtke, A.O., Matsubara, N., Park, S.H., Huddart, R.A., Burgess, E.F., Özgüroğlu, M., Valderrama, B.P., Laguerre, B., Basso, U., Triantos, S., Akapame, S., Kean, Y., Deprince, K., Mukhopadhyay, S., Loriot, Y.

Source: In Annals of Oncology January 2024 35(1):107-117

Postchemotherapy Surgery for Germ Cell Tumors

Authors: Riggs, S.B., Burgess, E.F., Gaston, K.E.

Source: ONCOLOGIST -MIAMISBURG-. 19(5):498-506

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN354390590&indx=1&recIds=ETOCRN354390590

Prostate Cancer: What Did We Learn From the 2012 Annual Scientific Meeting of ASCO?

Authors: Burgess, E.F., Raghavan, D.

Source: ONCOLOGY -WILLISTON PARK THEN HUNTINGTON THE MELVILLE NEW YORK-. 26(12):1216-1221

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN325163444&indx=1&recIds=ETOCRN325163444

208O Asian subgroup analysis of the THOR phase III study: Erdafitinib versus chemotherapy in patients with advanced or metastatic urothelial cancer and selected fibroblast growth factor receptor alterations

Authors: Matsubara, N., Loriot, Y., Burgess, E.F., Park, S.H., Huddart, R.A., Ku, J.H., Tran, B., Triantos, S., Deprince, K., Mukhopadhyay, S., Hemaya, R., Zhuo, J., Siefker-Radtke, A.O.

Source: In Annals of Oncology November 2023 34 Supplement 4:S1556-S1556

2359O Phase III THOR study: Results of erdafitinib (erda) vs pembrolizumab (pembro) in pretreated patients (pts) with advanced or metastatic urothelial cancer (muc) with select fibroblast growth factor receptor alterations (FGFRalt)

Authors: Siefker-Radtke, A.O., Matsubara, N., Park, S.H., Huddart, R.A., Burgess, E.F., Ozguroglu, M., Perez Valderrama, B., Triantos, S., Akapame, S., Kean, Y., Deprince, K., Mukhopadhyay, S., Loriot, Y.

Source: In Annals of Oncology October 2023 34 Supplement 2:S1199-S1199

LBA73 Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC)

Authors: Rosenberg, J.E., Milowsky, M., Ramamurthy, C., Mar, N., McKay, R.R., Friedlander, T., Ferrario, C., Bracarda, S., George, S., Moon, H., Geynisman, D., Petrylak, D.P., Borchiellini, D., Burgess, E.F., Rey, J.P. Maroto, Carret, A-S., Yu, Y., Guseva, M.V., Moreno, B. Homet, O'Donnell, P.H.

Source: In Annals of Oncology September 2022 33 Supplement 7:S1441-S1441

688P Gene expression profiling (GEP) signatures associated with markers of sensitivity to immune and angiogenic therapy in clear-cell renal cell carcinoma (ccRCC) with sarcomatoid/rhabdoid features

Authors: Coelho Barata, P.M., Gulati, S., Elliott, A., Rao, A., Burgess, E.F., McKay, R., Hammers, H.J., Gartrell, B., Darabi, S., Bilen, M.A., Geynisman, D., Dawson, N.A., Poorman, K., Zibelman, M., Zhang, T., Wei, S., Korn, W.M., Nabhan, C., Ryan, C.J., Heath, E.

Source: In Annals of Oncology September 2021 32 Supplement 5:S705-S705

651O Phase II trial of pembrolizumab (P) in combination with sEphB4-HSA (B4) in previously treated metastatic urothelial carcinoma (mUC)

Authors: Sadeghi, S., Quinn, D.I., Dorff, T., Pal, S.K., Groshen, S., Tsao-Wei, D., Lara, P.N., Parikh, R., Devitt, M.E., Parikh, M., Jackovich, A., Vogelzang, N.J., Burgess, E.F., Dreicer, R., Siddiqi, I., Gill, I., Gill, P.

Source: In Annals of Oncology September 2021 32 Supplement 5:S678-S678

751P Analysis of circulating tumor DNA (ctDNA) from the phase II BLC2001 trial of erdafitinib in locally advanced or metastatic urothelial carcinoma (mUC) to identify markers of intrinsic resistance to fibroblast growth factor receptor (FGFR)-targeted therapy

Authors: Siefker-Radtke, A.O., Loriot, Y., Necchi, A., Huddart, R.A., Burgess, E.F., Rezazadeh, A., O'Hagan, A., De Porre, P., Avadhani, A., Monga, M., Cherkas, Y., Moy, C.H., Santiago-Walker, A.

Source: In Annals of Oncology September 2020 31 Supplement 4:S584-S584

757P An observational study of outcomes of patients (pts) with advanced urothelial carcinoma (UC) after anti-programmed death-(Ligand) 1 (PD-[L]1) therapy by fibroblast growth factor receptor gene alteration (FGFRa) status

Authors: Rezazadeh, A., Loriot, Y., Papantoniou, D., Siefker-Radtke, A.O., Necchi, A., Naini, V., Santiago-Walker, A., Galluzzi, A., Monga, M., Burgess, E.F.

Source: In Annals of Oncology September 2020 31 Supplement 4:S586-S587

750P Erdafitinib (ERDA) in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC): Subgroup analyses of long-term efficacy outcomes of a pivotal phase II trial (BLC2001)

Authors: Necchi, A., Siefker-Radtke, A.O., Loriot, Y., Park, S.H., Garcia-Donas, J., Huddart, R.A., Burgess, E.F., Fleming, M.T., Rezazadeh, A., Mellado, B., Varlamov, S., Joshi, M., Duran, I., Zakharia, Y., Fu, M., Santiago-Walker, A., O'Hagan, A., Monga, M., Tagawa, S.T.

Source: In Annals of Oncology September 2020 31 Supplement 4:S583-S583

Observations From Early Adoption of Radium 223 (Ra-223) in Heavily Pretreated Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Authors: McHaffie, D.R., Sharp, H.J., Symanowski, J., Crimaldi, A.J., Mahoney, J., Burgess, E.F., Nazemzadeh, R., Haake, M.R.

Source: International journal of radiation oncology, biology, physics. 90(1):S440-S440

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100083818025.0x000001&indx=1&recIds=ETOCvdc_100083818025.0x000001